SBI Long Term Advantage Fund Series VI Direct - Growth
100000
2.04%
-0.19%
-0.04%
Apr 2025
Baroda BNP Paribas Flexi Cap Fund Direct - Growth
352416
1.57%
-0.14%
-0.07%
Apr 2025
Navi Large & Midcap Fund Direct-Growth
86000
1.55%
-0.14%
-0.05%
Apr 2025
Edelweiss Recently Listed IPO Fund Direct-Growth
280000
1.82%
-0.12%
0.17%
Apr 2025
SBI Innovative Opportunities Fund Direct-Growth
2088772
1.64%
-0.10%
0.46%
Apr 2025
Helios Balanced Advantage Fund Direct - Growth
59561
1.08%
-0.09%
-0.01%
Apr 2025
SBI Technology Opportunities Fund Direct-Growth
892860
1.16%
-0.07%
0.21%
Apr 2025
Navi Flexi Cap Fund Direct - Growth
47500
1.07%
-0.07%
-0.01%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.07%
-0.04%
Apr 2025
Navi Aggressive Hybrid Fund Direct - Growth
21500
1.03%
-0.05%
0.03%
Apr 2025
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
2706
0.29%
-0.03%
0.13%
Apr 2025
Invesco India Smallcap Fund Direct - Growth
353502
0.31%
-0.03%
-0.03%
Apr 2025
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
109477
0.29%
-0.03%
0.13%
Apr 2025
Bandhan BSE Healthcare Index Fund Direct-Growth
1092
0.33%
-0.03%
0.11%
Apr 2025
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
6422
0.30%
-0.02%
0.14%
Apr 2025
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
44316
0.30%
-0.02%
0.14%
Apr 2025
WhiteOak Capital Multi Cap Fund Direct - Growth
40918
0.13%
-0.02%
-0.02%
Apr 2025
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
24316
0.30%
-0.02%
0.14%
Apr 2025
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
11441
0.17%
-0.02%
-0.03%
Apr 2025
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
22704
0.30%
-0.02%
0.14%
Apr 2025
About Indegene
Indegene Limited is a global provider of digital-led commercialization services for the life sciences industry. The company offers solutions in analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical devices companies. Indegene operates through four main segments: Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Others. These segments assist with digital marketing operations, last-mile promotion optimization, regulatory and medical operations consolidation, and clinical solutions and consultancy services. The company has made several acquisitions to expand its capabilities, including Encima Group, DT Associates, Cult Health, and Trilogy Writing & Consulting GmbH. In 2023, Indegene launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform. The company completed a public issue in May 2024, raising funds through a fresh issue and offer for sale.